Clinical trial NCT04316091: A Phase I Clinical Trial of Neoadjuvant Chemotherapy With/Without SPIONs/SMF for Patients With Osteosarcoma
Official title: A Phase I Clinical Trial of Neoadjuvant Chemotherapy With/Without Superparamagnetic Iron Oxide Nanoparticles and Spinning Magnetic Field for Patients With Osteosarcoma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Osteosarcoma
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
Collaborators: name: Leiden University Medical Center
First posted: 2020-03-20
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Osteosarcoma is the most common primary malignant bone tumor that mainly occurs in children and adolescents. Combined surgical resection and intensive chemotherapy has improved the 5-year overall survival rate (from 51 to 75%). However, drug-induced side effects and tumor recurrence after surgery reduce patient quality of life and cut down the patient survival rate. Superparamagnetic Iron Oxide Nanoparticles (SPIONs)/Spinning Magnetic Field (SMF) and neoadjuvant chemotherapy may increase the cancer cell killing and complete tumor shrinkage preserving local structures and functions of patients who cannot receive limb retention treatment.

Detailed description: This study aims to evaluate the safety, efficacy, and tolerability of SPIONs/SMF in combination with neoadjuvant chemotherapy in osteosarcoma patients. They will receive intratumoral injection of SPIONs every other day for 3 times, followed by SMF for 2 hours every two days, and up to completion of 30 days, and conventional neoadjuvant chemotherapy from day 1. The sponsor hypothesizes that SPIONs/SMF will act synergistically with neoadjuvant chemotherapy to increase the cancer cell killing, to increase the local efficacy of neoadjuvant chemotherapy, and to improve the ratio of limb retention. Then, all patients will be followed every 8 weeks, for the safety evaluation and cancer disease status until the end of the study.

Eligibility criteria: Inclusion Criteria:

* Signed informed consent form
* Biopsy-confirmed cancer diagnosis
* Has at least one tumor lesion that can be accurately measured according to RECIST 1.1. and is amenable for intratumoral injection
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Life expectancy \>12 weeks
* Karnofsky performance status (KPS) ≥ 70
* Adequate function of organs and bone marrow
* Negative pregnancy test ≤ 7 days prior to SPIONs injection

Exclusion Criteria:

* Symptomatic central nervous system metastases and/or carcinomatous meningitis
* Known HIV or active hepatitis B/C infection
* Active infection requiring systemic treatment
* Received a live virus vaccine within 30 days prior to study treatment
* History of pneumonitis that required steroids or with current pneumonitis
* Has received prior systemic anti-neoplastic therapy, within 4 weeks prior to SPIONs injection
* Clinically significant cardiac arrhythmias
* Class III or IV Congestive Heart Failure as defined by the New York Heart Association functional classification system \< 6 months prior to screening
* A pregnant or nursing female, or women of child-bearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception
* Any condition for which participation would not be in the best interest of the participant
* Patients unable to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures or those with severe psychiatric illness/social situations that would limit compliance with study requirements
* Patients participating in another clinical investigation at the time of signature of the informed consent

Primary outcomes:
measure: Determination of the Recommended Dose
timeFrame: 36 Months
Secondary outcomes:
measure: Evaluation of the anti-tumor response of neoadjuvant chemotherapy±SPIONs/SMF
timeFrame: 36 Months
measure: Assessment of the safety and feasibility of neoadjuvant chemotherapy±SPIONs/SMF
timeFrame: 36 Months
measure: Evaluation of the body kinetic profile of intratumorally injected neoadjuvant chemotherapy±SPIONs/SMF
timeFrame: 36 Months
Other outcomes:
Locations:
Study officials:
References: